{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:47:57Z","timestamp":1793040477979,"version":"4.5.0"},"reference-count":38,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2004,8,17]],"date-time":"2004-08-17T00:00:00Z","timestamp":1092700800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2004,9]]},"abstract":"<jats:p><jats:bold>BACKGROUND:\u2002<\/jats:bold> Cellular assays (e.g., monocyte monolayer assays [MMAs]) have been used to predict the clinical significance of red blood cell (RBC) alloantibodies.<\/jats:p><jats:p><jats:bold>STUDY DESIGN AND METHODS:\u2002<\/jats:bold> Twenty years of MMA data were retrospectively analyzed to 1) determine the optimal cut point (by correlating MMA results from 46 patients with RBC survival study results and\/or laboratory and clinical signs of hemolytic transfusion reactions [HTRs] when incompatible blood was transfused), and 2) determine what percentage of 251 unusual alloantibodies (most to high\u2010incidence antigens) were predicted to be clinically significant.<\/jats:p><jats:p><jats:bold>RESULTS:\u2002<\/jats:bold> Two MMA cut points (5% and 20%) were chosen using a receiver\u2010operating characteristics curve. No patients with MMA results less than or equal to 5 percent had clinical signs of a reaction; one\u2010third of patients with MMA results 5.1 to 20 percent versus two\u2010thirds with results greater than 20 percent had clinical signs of a HTR after transfusion of incompatible blood. Using 5\u2010percent or 20\u2010percent cut points, 173 (69%) or 97 (39%) of 251 unusual alloantibodies gave positive MMAs, respectively.<\/jats:p><jats:p><jats:bold>CONCLUSION:\u2002<\/jats:bold> A negative MMA (\u22645%) indicates that incompatible blood can be given without risk of an overt HTR but does not guarantee normal long\u2010term survival of those RBCs. Most unusual alloantibodies are predicted to cause shortened RBC survival, but transfusion of incompatible blood may not result in any clinical or laboratory signs of a HTR. We have used the MMA for approximately 20 years, instead of a 1\u2010hour chromium\u201051 RBC survival, to aid in the decision to transfuse RBCs incompatible with antibodies to high\u2010incidence antigens.<\/jats:p>","DOI":"10.1111\/j.1537-2995.2004.03427.x","type":"journal-article","created":{"date-parts":[[2004,8,17]],"date-time":"2004-08-17T09:10:39Z","timestamp":1092733839000},"page":"1273-1281","source":"Crossref","is-referenced-by-count":104,"title":["A retrospective analysis of the value of monocyte monolayer assay results for predicting the clinical significance of blood group alloantibodies"],"prefix":"10.1111","volume":"44","author":[{"given":"Patricia A.","family":"Arndt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Garratty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,8,17]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1998.tb05433.x"},{"key":"e_1_2_7_3_2","unstructured":"IssittPD AnsteeD.Applied blood group serology 4th ed.Durham NC: Montgomery Scientific 1998."},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1981.21582040822.x"},{"key":"e_1_2_7_5_2","unstructured":"GarrattyG.Predicting the clinical significance of alloantibodies and determining the in vivo survival of transfused red cells. In:JuddWJ BarnesA eds.Clinical and serological aspects of transfusion reactions: a technical workshop. Washington DC: American Association of Blood Banks 1982:91\u2010119."},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1984.tb01268.x"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1985.25185116499.x"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1987.27688071692.x"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0887-7963(90)70272-6"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3148.1999.00218.x"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1984.24284173358.x"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1986.26386209380.x"},{"key":"e_1_2_7_13_2","first-page":"534","article-title":"Hydrops fetalis (HF) and a maternal hemolytic transfusion reaction associated with anti\u2010Jsb (abstract)","volume":"27","author":"Ratcliff D","year":"1987","journal-title":"Transfusion"},{"key":"e_1_2_7_14_2","first-page":"11","article-title":"Clinical management of transfusion therapy in a patient with anti\u2010Yta","volume":"5","author":"Smart JA.","year":"1987","journal-title":"CBBS Today"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1988.28588337342.x"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1988.28388219157.x"},{"key":"e_1_2_7_17_2","first-page":"37S","article-title":"Clinical significance of anti\u2010Lu8 in a patient who received Lu: 8 red cells (abstract)","volume":"28","author":"Kobuszewski M","year":"1988","journal-title":"Transfusion"},{"key":"e_1_2_7_18_2","first-page":"37S","article-title":"51Cr radiolabeled survival studies in a patient with anti\u2010Lu12 (abstract)","volume":"28","author":"Shirey RS","year":"1988","journal-title":"Transfusion"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1994.tb00311.x"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1995.351196110897.x"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1995.35195090666.x"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1995.tb01684.x"},{"key":"e_1_2_7_23_2","doi-asserted-by":"crossref","first-page":"93","DOI":"10.21307\/immunohematology-2019-715","article-title":"Clinical significance of an anti\u2010Dib assessed by flow cytometry","volume":"13","author":"Leger R","year":"1997","journal-title":"Immunohematology"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2004.00643.x"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1988.tb05087.x"},{"key":"e_1_2_7_26_2","first-page":"37S","article-title":"Monocyte monolayer assay (MMA) results are affected by transfusion of incompatible red cells (abstract)","volume":"37","author":"Nance S","year":"1997","journal-title":"Transfusion"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1983.23584018719.x"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197507312930501"},{"key":"e_1_2_7_29_2","first-page":"832","article-title":"Interpretation of diagnostic data: 4. How to do it with a more complex table","volume":"129","author":"Tugwell PX.","year":"1983","journal-title":"Can Med Assoc J"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1086\/501760"},{"key":"e_1_2_7_31_2","volume-title":"Beyond normality. The predictive value and efficiency of medical diagnoses","author":"Galen RS","year":"1975"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1988.28488265281.x"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1983.23283172845.x"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2003.00469.x"},{"key":"e_1_2_7_35_2","first-page":":561","volume-title":"Blood transfusion in clinical medicine","author":"Mollison PL","year":"1997"},{"key":"e_1_2_7_36_2","volume-title":"Standards for blood banks and transfusion services","author":"Fridey J","year":"2003"},{"key":"e_1_2_7_37_2","first-page":"13","author":"National Blood Service guidance for the selection of blood for patients with common and rare red cell antibodies.","year":"2003","journal-title":"Blood Matters"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3148.2002.00399.x"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2003.00565.x"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1537-2995.2004.03427.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1537-2995.2004.03427.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1537-2995.2004.03427.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T02:15:30Z","timestamp":1697249730000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1537-2995.2004.03427.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,8,17]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2004,9]]}},"alternative-id":["10.1111\/j.1537-2995.2004.03427.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1537-2995.2004.03427.x","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,8,17]]}}}